Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	i3 Verticals	QuinStreet	Viad	Capita	OptimizeRx
Symbol	NASDAQ:IIIV	NASDAQ:QNST	NYSE:VVI	OTCMKTS:CTAGY	NASDAQ:OPRX
Price Information
Current Price	$31.92	$18.34	$45.85	$2.09	$55.27
50-Day Moving Average	$31.38	$18.21	$47.49	$2.25	$53.87
52-Week Low	$20.25	$11.14	$13.94	$2.09	$13.84
52-Week High	$35.99	$25.99	$52.00	$2.60	$63.98
MarketRank™
Overall Score	2.7	2.5	2.0	0.7	2.5
Analysis Score	2.4	3.5	2.5	0.0	3.5
Community Score	4.4	4.1	5.0	3.6	4.5
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	5.0	2.5	1.7	0.0	2.5
Earnings & Valuation Score	1.9	2.5	0.6	0.0	1.9
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	N/A	Buy
Consensus Price Target	$37.25	$26.00	$56.00	N/A	$71.00
% Upside from Price Target	16.70% upside	41.77% upside	22.14% upside	N/A	28.46% upside
Trade Information
Market Cap	$1.03 billion	$983.37 million	$939.19 million	$880.03 million	$965.46 million
Beta	1.61	0.91	2.04	1.29	0.65
Average Volume	59,232	171,288	135,492	6	113,091
Sales & Book Value
Annual Revenue	$150.13 million	$490.34 million	$415.43 million	$4.27 billion	$43.31 million
Price / Sales	6.84	2.01	2.26	0.21	22.29
Cashflow	$1.20 per share	$0.57 per share	N/A	$0.87 per share	$0.13 per share
Price / Cash	26.69	32.21	N/A	2.40	421.75
Book Value	$7.81 per share	$4.93 per share	$8.52 per share	($0.25) per share	$3.31 per share
Price / Book	4.09	3.72	5.38	-8.36	16.70
Profitability
Net Income	$-420,000.00	$18.10 million	$-374,090,000.00	$17.98 million	$-2,210,000.00
EPS	$0.51	$0.34	($5.85)	N/A	N/A
Trailing P/E Ratio	N/A	45.85	N/A	0.00	1,842.95
Forward P/E Ratio	34.32	73.36	24.39	∞	80.10
P/E Growth	2.37	N/A	N/A	N/A	N/A
Net Margins	-1.95%	3.98%	-219.60%	N/A	1.35%
Return on Equity (ROE)	6.18%	7.91%	-79.87%	N/A	0.82%
Return on Assets (ROA)	3.08%	5.31%	-16.51%	N/A	0.72%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	-75.00%	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.63%	N/A	2.63%	N/A	N/A
Current Ratio	0.55%	1.74%	0.89%	0.49%	18.51%
Quick Ratio	0.55%	1.74%	0.81%	0.49%	18.52%
Ownership Information
Institutional Ownership Percentage	62.47%	86.76%	89.32%	N/A	64.72%
Insider Ownership Percentage	31.90%	9.00%	1.80%	N/A	6.50%
Miscellaneous
Employees	740	592	1,697	37,000	71
Shares Outstanding	32.16 million	53.62 million	20.48 million	421.07 million	17.47 million
Next Earnings Date	8/9/2021 (Confirmed)	8/4/2021 (Confirmed)	8/5/2021 (Confirmed)	N/A	8/4/2021 (Confirmed)
Optionable	Not Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Douglas P. Baker Sells 3,000 Shares of OptimizeRx Co. (NASDAQ:OPRX) Stock americanbankingnews.com - July 28 at 7:26 PM
	OptimizeRx Corp. (OPRX) Reports Next Week: Wall Street Expects Earnings Growth finance.yahoo.com - July 28 at 7:21 PM
	OptimizeRx (OPRX) Scheduled to Post Quarterly Earnings on Wednesday americanbankingnews.com - July 28 at 9:01 AM
	OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET - The Bakersfield Californian bakersfield.com - July 28 at 8:27 AM
	OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET - Yahoo Finance finance.yahoo.com - July 27 at 9:31 AM
	OptimizeRx Sets Second Quarter Fiscal 2021 Conference Call for Wednesday, August 4 at 4:30 p.m. ET finance.yahoo.com - July 27 at 9:31 AM
	Insider Selling: OptimizeRx Co. (NASDAQ:OPRX) CFO Sells 3,000 Shares of Stock americanbankingnews.com - July 21 at 7:12 PM
	OptimizeRx Co. (NASDAQ:OPRX) Insider Sells $666,602.28 in Stock americanbankingnews.com - July 21 at 7:12 PM
	Insider Selling: OptimizeRx Co. (NASDAQ:OPRX) Director Sells 60,000 Shares of Stock americanbankingnews.com - July 20 at 10:24 AM
	$12.35 Million in Sales Expected for OptimizeRx Co. (NASDAQ:OPRX) This Quarter americanbankingnews.com - July 18 at 2:04 AM
	OptimizeRx Co. (NASDAQ:OPRX) Expected to Announce Earnings of $0.07 Per Share americanbankingnews.com - July 16 at 9:14 PM
	Form 8-K OptimizeRx Corp For: Jul 14 - StreetInsider.com streetinsider.com - July 15 at 12:16 AM
	OptimizeRx Announces Agreement with a Top Pharmaceutical - GlobeNewswire globenewswire.com - July 14 at 2:15 PM
	OptimizeRx Announces Agreement with a Top Pharmaceutical Manufacturer to Use its Evidence-Based Physician Engagement to Solve Lapse in Medical Coverage Barrier for Patients finance.yahoo.com - July 14 at 9:14 AM
	Fund Manager Ryan Jacob Takes On Cathie Wood's ARK Funds With New ETF - Barron's barrons.com - July 13 at 6:13 PM
	Q2 2021 Earnings Forecast for OptimizeRx Co. Issued By B. Riley (NASDAQ:OPRX) americanbankingnews.com - July 12 at 1:08 AM
	OptimizeRx Co. (NASDAQ:OPRX) CFO Sells $753,031.75 in Stock americanbankingnews.com - July 9 at 7:11 PM
	Want $3,895 per Month in Social Security Benefits? Here's the Salary You Need - Nasdaq nasdaq.com - July 9 at 8:20 AM
	2 Top Small-Cap Stocks to Buy in July - Nasdaq nasdaq.com - July 8 at 12:47 PM
	Zacks Investment Research Lowers OptimizeRx (NASDAQ:OPRX) to Hold marketbeat.com - July 8 at 9:00 AM
	2 Top Small-Cap Stocks to Buy in July - Motley Fool fool.com - July 8 at 7:47 AM
	OptimizeRx (NASDAQ:OPRX) Shares Gap Down to $58.51 americanbankingnews.com - July 7 at 12:37 PM
	Returns On Capital Are Showing Encouraging Signs At OptimizeRx (NASDAQ:OPRX) - Yahoo Finance finance.yahoo.com - July 5 at 2:24 PM
	Returns On Capital Are Showing Encouraging Signs At OptimizeRx (NASDAQ:OPRX) finance.yahoo.com - July 5 at 2:24 PM
	President Biden holds wildfire prevention conference - Yahoo News news.yahoo.com - July 2 at 8:01 AM
	OptimizeRx Corp. (OPRX) Upgraded to Strong Buy: Here's Why - Yahoo Finance finance.yahoo.com - July 1 at 2:49 PM

Date	Company	Brokerage	Action
7/26/2021	i3 Verticals	Morgan Stanley	Initiated Coverage
5/26/2021	Viad	B. Riley	Initiated Coverage
5/7/2021	OptimizeRx	B. Riley	Boost Price Target
4/12/2021	OptimizeRx	Royal Bank of Canada	Initiated Coverage
2/25/2021	OptimizeRx	B. Riley	Boost Price Target
2/25/2021	OptimizeRx	Roth Capital	Boost Price Target
2/10/2021	i3 Verticals	KeyCorp	Boost Price Target
2/10/2021	i3 Verticals	Raymond James	Boost Price Target
2/9/2021	i3 Verticals	DA Davidson	Boost Price Target
2/4/2021	QuinStreet	Barrington Research	Boost Price Target
2/4/2021	QuinStreet	Lake Street Capital	Boost Price Target
1/26/2021	OptimizeRx	Lake Street Capital	Boost Price Target
1/14/2021	i3 Verticals	Raymond James	Boost Price Target
1/7/2021	OptimizeRx	Lake Street Capital	Boost Price Target
1/7/2021	OptimizeRx	Roth Capital	Boost Price Target
1/6/2021	i3 Verticals	BTIG Research	Boost Price Target
1/6/2021	i3 Verticals	Bank of America	Downgrade
1/4/2021	OptimizeRx	B. Riley	Boost Price Target
12/21/2020	i3 Verticals	Piper Sandler	Initiated Coverage
12/15/2020	i3 Verticals	Stephens	Initiated Coverage
12/11/2020	QuinStreet	Barrington Research	Boost Price Target
11/10/2020	OptimizeRx	Lake Street Capital	Boost Price Target
11/10/2020	OptimizeRx	B. Riley	Boost Price Target
10/20/2020	QuinStreet	Lake Street Capital	Boost Price Target
9/23/2020	i3 Verticals	Raymond James	Upgrade
9/14/2020	OptimizeRx	Roth Capital	Boost Price Target
9/3/2020	QuinStreet	Barrington Research	Upgrade
8/17/2020	QuinStreet	Barrington Research	Reiterated Rating
8/12/2020	i3 Verticals	Raymond James	Boost Price Target
8/12/2020	i3 Verticals	KeyCorp	Boost Price Target
8/11/2020	i3 Verticals	BTIG Research	Upgrade
8/6/2020	OptimizeRx	B. Riley	Boost Price Target
8/6/2020	OptimizeRx	Lake Street Capital	Boost Price Target
6/26/2020	Capita	JPMorgan Chase & Co.	Reiterated Rating
6/19/2020	i3 Verticals	Cowen	Boost Price Target
6/17/2020	i3 Verticals	BTIG Research	Downgrade
6/8/2020	OptimizeRx	Lake Street Capital	Boost Price Target
5/28/2020	QuinStreet	Barrington Research	Reiterated Rating
5/13/2020	QuinStreet	Barrington Research	Reiterated Rating
5/11/2020	i3 Verticals	Raymond James	Lower Price Target
5/10/2020	i3 Verticals	BTIG Research	Reiterated Rating
5/7/2020	QuinStreet	Barrington Research	Reiterated Rating
5/7/2020	QuinStreet	Lake Street Capital	Lower Price Target
5/5/2020	OptimizeRx	B. Riley	Boost Price Target
4/16/2020	QuinStreet	Barrington Research	Downgrade
4/7/2020	OptimizeRx	B. Riley	Lower Price Target
3/31/2020	Viad	Sidoti	Lower Price Target
3/23/2020	i3 Verticals	BTIG Research	Upgrade
3/23/2020	i3 Verticals	KeyCorp	Lower Price Target
3/5/2020	Viad	Sidoti	Lower Price Target
2/28/2020	i3 Verticals	DA Davidson	Upgrade
2/12/2020	i3 Verticals	DA Davidson	Downgrade
2/11/2020	i3 Verticals	BTIG Research	Downgrade
2/6/2020	QuinStreet	Barrington Research	Boost Price Target
2/6/2020	QuinStreet	Barrington Research	Reiterated Rating
1/16/2020	i3 Verticals	BTIG Research	Reiterated Rating
1/3/2020	OptimizeRx	William Blair	Initiated Coverage
12/30/2019	OptimizeRx	B. Riley	Lower Price Target
9/27/2019	i3 Verticals	Bank of America	Upgrade
9/5/2019	i3 Verticals	BTIG Research	Set Price Target
8/15/2019	QuinStreet	Barrington Research	Lower Price Target
8/12/2019	QuinStreet	Northland Securities	Reiterated Rating
8/9/2019	QuinStreet	Stephens	Set Price Target
6/24/2019	QuinStreet	Lake Street Capital	Initiated Coverage
5/16/2019	QuinStreet	Barrington Research	Reiterated Rating
3/7/2019	QuinStreet	Singular Research	Reiterated Rating
1/3/2019	OptimizeRx	William Blair	Initiated Coverage
11/15/2018	Viad	Janney Montgomery Scott	Initiated Coverage
10/31/2018	QuinStreet	Craig Hallum	Reiterated Rating
10/4/2018	QuinStreet	William Blair	Initiated Coverage
9/28/2018	OptimizeRx	Roth Capital	Boost Price Target
9/17/2018	OptimizeRx	Lake Street Capital	Boost Price Target
8/8/2018	OptimizeRx	B. Riley	Boost Price Target
8/8/2018	OptimizeRx	Lake Street Capital	Boost Price Target
8/7/2018	QuinStreet	Stephens	Reiterated Rating

(Data available from 8/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources